"Desloratadine"@en . . . . "8-Chloro-11-piperidin-4-ylidene-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine"@en . . . . . "Humans and other mammals"@en . . "investigational"@en . "approved"@en . . . . "82-87%"@en . . . . . . "100643-71-8"@en . . . . . . . . "For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria."@en . . . . . . . . . . . . . " "@en . . . "Zoltan Toth, \"Processes for preparation of polymorphic forms of desloratadine.\" U.S. Patent US20040242619, issued December 02, 2004."@en . . . . . . . . . . . . . . . . "50 hours"@en . . "Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. Approximately 87% of a 14C-desloratadine dose was equally recovered in urine and feces."@en . . "Take without regard to meals."@en . "Descarboethoxyloratadine"@en . . . . "Like other H1-blockers, Desloratadine competes with free histamine for binding at H₁-receptors in the GI tract, uterus, large blood vessels, and bronchial smooth muscle. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms (eg. nasal congestion, watery eyes) brought on by histamine."@en . . . "Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system."@en . . . . . . "# Mann RD, Pearce GL, Dunn N, Shakir S: Sedation with \"non-sedating\" antihistamines: four prescription-event monitoring studies in general practice. BMJ. 2000 Apr 29;320(7243):1184-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/10784544 # Glass DJ, Harper AS: Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine. BMC Fam Pract. 2003 Aug 13;4:10. Epub 2003 Aug 13. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12917016 # See S: Desloratadine for allergic rhinitis. Am Fam Physician. 2003 Nov 15;68(10):2015-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/14655812 # Devillier P, Roche N, Faisy C: Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review. Clin Pharmacokinet. 2008;47(4):217-30. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/18336052 # Bachert C: A review of the efficacy of desloratadine, fexofenadine, and levocetirizine in the treatment of nasal congestion in patients with allergic rhinitis. Clin Ther. 2009 May;31(5):921-44. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/19539095 # DuBuske L: Desloratadine for chronic idiopathic urticaria: a review of clinical efficacy. Am J Clin Dermatol. 2007;8(5):271-83. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17902729 # Bachert C, Maurer M: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin Drug Investig. 2010;30(2):109-22. doi: 10.2165/11530930-000000000-00000. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/20067329 # Simons FE, Prenner BM, Finn A Jr: Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003 Mar;111(3):617-22. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/12642846"@en . "DESLORATADINE"@en . . . "8-chloro-6,11-dihydro-11-(4-Piperidinylidene)-5H-benzo(5,6)cyclohepta(1,2-b)pyridine"@en . . . . . . .